Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015

FLEMINGTON, N.J., April 13, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced the upcoming presentation of three posters supporting the ongoing clinical development program for lead compound onapristone at the American Association for Cancer Research (AACR) Annual Meeting 2015, being held April 18-22 in Philadelphia, PA.

Details for the three poster presentations are as follows:

Tuesday, April 21; 1:00-5:00 p.m. ET

Poster Session: PO.ET05.01. Pharmacokinetics and Pharmacodynamics

  • Abstract #4512 (Poster #10) – Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study
  • Abstract #4523 (Poster #21) – Population pharmacokinetic (PPK) modeling of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers

Tuesday, April 21; 8:00 a.m. - 12:00 p.m. ET

Poster Session: PO.EN02.01. Hormonal Regulation of Tumor Growth and Metastasis

  • Abstract #3471 (Poster #24) – Comparative assessment of in vitro activity and activated progesterone receptor (APR) biomarker predictivity for multiple antiprogestins

Arno is currently enrolling patients in a Phase II clinical trial of onapristone in patients with metastatic or recurrent endometrioid tumors that express the activated progesterone receptor (APR), and in a separate Phase I/II clinical trial of onapristone in patients with castration resistant prostate cancer whose tumors are progesterone receptor (PR) positive.

Onapristone is an oral, anti-progestin hormone blocker that has been shown in previous Phase II clinical trials (not sponsored by Arno) to exhibit anti-tumor activity in patients with breast cancer. In pre-clinical testing, onapristone has been shown to block the activation of PR, which is believed to be a mechanism that inhibits the growth of APR driven breast, endometrial and other, primarily gynecological tumors. APR has the potential to function as a biomarker of anti-progestin activity, as detected by a companion diagnostic currently under development with Arno's partner, Leica Biosystems.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. Arno has exclusive worldwide rights to develop and market three innovative product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors, as well as infectious diseases. For more information about the company, please visit

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, including the ability to identify and treat those patients most likely to benefit from onapristone, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. Arno may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made here. Various important factors could cause actual results or events to differ materially from these forward-looking statements. Such factors include, among others, risks that the results of clinical trials will not support claims or beliefs concerning the effectiveness of onapristone or any other product candidates, the ability to successfully develop a diagnostic to identify APR tumors, the ability to finance the development of Arno's product candidates, regulatory risks, and reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2014. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

CONTACT: The Ruth Group Lee Roth (investors) (646) 536-7012 Kirsten Thomas (media) (646) 536-7014 Arno Therapeutics Lawrence Kenyon (862) 703-7171

Source:Arno Therapeutics Inc.